These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 8769189)

  • 61. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
    Vathsala A; Lee WT; Lu YM; Woo KT
    Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
    [No Abstract]   [Full Text] [Related]  

  • 62. Sandimmun and Neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant.
    De Palma MT; Giordano M; Colella V; Palumbo F; De Nicolo VE; Caringella DA
    Transplant Proc; 1998 Aug; 30(5):1677. PubMed ID: 9723239
    [No Abstract]   [Full Text] [Related]  

  • 63. Oral cyclosporine preparations immediately following renal transplantation.
    Katz SM; Amante A; Schoenberg L; Kahan BD
    Transplant Proc; 1996 Aug; 28(4):2164. PubMed ID: 8769188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients.
    Gaston R; Alloway RR; Gaber AO; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; First MR
    Transplant Proc; 1999; 31(1-2):326-7. PubMed ID: 10083128
    [No Abstract]   [Full Text] [Related]  

  • 65. An open randomized parallel group study to compare Sandimmune Neoral with Sandimmune soft gelatin capsule in stable renal transplant patients.
    Park K; Koh YB; Kwak JY; Kim SJ; Yoon YS; Kang CM; Kim YS
    Transplant Proc; 1996 Jun; 28(3):1202-3. PubMed ID: 8658627
    [No Abstract]   [Full Text] [Related]  

  • 66. Cyclosporine neoral in liver transplant recipients.
    Levy G; Altraif I; Rezieg M; Asfar S; Rochon J; Freeman D; Wong PY; Banks L; Roach C; Engel K
    Transplant Proc; 1994 Dec; 26(6):3184-7. PubMed ID: 7998109
    [No Abstract]   [Full Text] [Related]  

  • 67. Sandimmun Neoral: Taiwanese experience in renal transplant patients with special reference to patients with existing liver disease.
    Lee PH; Hu RH; Tsai KS; Chern HD; Gau YS; Chen RR
    Transplant Proc; 1996 Jun; 28(3):1327. PubMed ID: 8658679
    [No Abstract]   [Full Text] [Related]  

  • 68. Enhanced absorption of new oral cyclosporin microemulsion formulation, Neoral, in liver transplant recipients with external biliary diversion.
    Trull AK; Tan KK; Tan L; Alexander GJ; Jamieson NV
    Transplant Proc; 1994 Oct; 26(5):2977-8. PubMed ID: 7940939
    [No Abstract]   [Full Text] [Related]  

  • 69. Neoral cyclosporine.
    Canafax DM
    Transplant Proc; 1996 Apr; 28(2):867. PubMed ID: 8623439
    [No Abstract]   [Full Text] [Related]  

  • 70. Abbreviating area under the curves further: a practical approach to monitoring extended pharmacokinetics with Neoral.
    Sindhi R; Shah J; Foley L; Bucsis J; Kyryliuk T; Baliga PK; Rajagopalan PR
    Transplant Proc; 1998 Jun; 30(4):1197-8. PubMed ID: 9636485
    [No Abstract]   [Full Text] [Related]  

  • 71. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.
    Cooney GF; Jeevanandam V; Choudhury S; Feutren G; Mueller EA; Eisen HJ
    Transplant Proc; 1998 Aug; 30(5):1892-4. PubMed ID: 9723323
    [No Abstract]   [Full Text] [Related]  

  • 72. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
    Crocker J; Renton K; Wade A; McLellan H; Acott P
    Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369
    [No Abstract]   [Full Text] [Related]  

  • 73. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant.
    Rial MC; Frias S; Argento J; Tessler J; Casadei D
    Transplant Proc; 1997; 29(1-2):292-3. PubMed ID: 9123001
    [No Abstract]   [Full Text] [Related]  

  • 74. The pharmacokinetics of oral cyclosporin A (Neoral) during the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Toze CL; Corr T; Currie C; Strong DK; Keown PA
    Transplant Proc; 1998 Aug; 30(5):1668-70. PubMed ID: 9723236
    [No Abstract]   [Full Text] [Related]  

  • 75. Diet and cyclosporin A--pharmacokinetic comparison between Neoral and Sandimmune gelatin capsules.
    Browne BJ; Jordan S; Welsh MS; Van Buren C; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):2959-60. PubMed ID: 7940934
    [No Abstract]   [Full Text] [Related]  

  • 76. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
    Wilczek HE; Akesson P; Warholm C
    Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
    [No Abstract]   [Full Text] [Related]  

  • 77. Comparative study of population pharmacokinetics upon switching of cyclosporine formulation from Sandimmune to Neoral in stable renal transplant patients.
    Yoshida K; Kimura T; Hamada Y; Saito T; Endo T; Baba S; Shimada S
    Transplant Proc; 2001; 33(7-8):3146-7. PubMed ID: 11750351
    [No Abstract]   [Full Text] [Related]  

  • 78. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 79. A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral.
    Loo CS; Morad Z; Lim TO; Fan KS; Suleiman AB
    Transplant Proc; 1996 Jun; 28(3):1328-9. PubMed ID: 8658680
    [No Abstract]   [Full Text] [Related]  

  • 80. Comparison of cyclosporine absorption profiles over a 12-month period in stable pediatric renal transplant recipients.
    Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R
    Transplant Proc; 2003 Jun; 35(4):1300-3. PubMed ID: 12826143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.